Advertisement

Topics

Bristol-Myers Squib in Collaboration to Evaluate Opdivo Combo Drug

06:15 EDT 1 Aug 2017 | PharmPro

Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration to evaluate combination of Opdivo (nivolumab) and Rubraca (rucaparib) in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types.
Contributed Author: 
Bristol-Myers Squibb Company

Original Article: Bristol-Myers Squib in Collaboration to Evaluate Opdivo Combo Drug

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squib in Collaboration to Evaluate Opdivo Combo Drug"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...